ab                                                                                                       Global Equity Res...
US Morning Meeting Highlights 22 August 2011EconomicsEconomics                                                       Maury...
US Morning Meeting Highlights 22 August 2011Basic Materials                                                               ...
US Morning Meeting Highlights 22 August 2011Energy                                                                        ...
US Morning Meeting Highlights 22 August 2011                                                                              ...
US Morning Meeting Highlights 22 August 2011                                                                              ...
US Morning Meeting Highlights 22 August 2011Industrial                                                                    ...
US Morning Meeting Highlights 22 August 2011                                                                              ...
US Morning Meeting Highlights 22 August 2011                                                                              ...
US Morning Meeting Highlights 22 August 2011Economics                                                                     ...
US Morning Meeting Highlights 22 August 2011                                                                              ...
US Morning Meeting Highlights 22 August 2011Equity Strategy                                                               ...
US Morning Meeting Highlights 22 August 2011Required DisclosuresThis package has been prepared by UBS Securities LLC, an a...
US Morning Meeting Highlights 22 August 2011UK and European Investment Fund ratings and definitions are: Buy: Positive on ...
US Morning Meeting Highlights 22 August 2011Company DisclosuresCompany Name                                               ...
US Morning Meeting Highlights 22 August 2011          gas storage facilities in Germany to GDF Suez4a.       Within the pa...
US Morning Meeting Highlights 22 August 2011please contact UBS Securities LLC, 1285 Avenue of Americas, New York, NY 10019...
US Morning Meeting Highlights 22 August 2011Global DisclaimerThis package has been prepared by UBS Securities LLC, an affi...
Upcoming SlideShare
Loading in …5

Financial Pacific - Better than expected adcetris label (third party)


Published on

Visit our website for more information: http://www.investingpacific.com/
Financial Pacific: “The Right Wave to Invest”

License CNV 319-03

In today’s global economy it is important to be fully aware of the intricacies of international investments and the opportunities that these have to offer. Financial Pacific offers proven overseas investment opportunities.
If you are interested in a reliable investment institution look no further because Financial Pacific provides: Wealth Management, Online Trading, Institutional Services and Corporate Finance. With cutting edge technology we are capable to support highly specialized derivatives instruments such as: CFDs, ETFs, CFDs on Commodities, ETCs, Futures and Options. In addition investors have access to a wide range of investment opportunities through: Structured Notes, Fixed Income, Reverse Convertibles, Preferred Stocks, and Institutional Hedge Funds.
Fully regulated by Comisión Nacional de Valores de Panama since 2003; allow us to provide you with the necessary tools to take advantage of the global markets.

Published in: Business, Economy & Finance
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Financial Pacific - Better than expected adcetris label (third party)

  1. 1. ab Global Equity ResearchUBS Investment ResearchUS Morning Meeting Highlights - 22 August 2011 http://www.ubs.com/investmentresearchEstimate/Price Target RevisionsDHT Holdings, Inc., DHT.N Rick Paterson p.7Cutting Estimates12-month rating: Neutral * (Unchanged) CBE , FY11E US$0.37=>US$0.26, FY12EUS$0.45=>US$0.33, PT Prior: US$4.30 => US$2.75, Market cap. US$0.18bnCompany UpdateCareFusion, CFN.N Rajeev Jashnani, CFA p.5Update from CFO12-month rating: Buy (Unchanged), FY11E US$1.65, FY12E US$1.87, PT US$26.00,Market cap. US$5.28bnMedtronic, MDT.N Rajeev Jashnani, CFA p.6F1Q12 preview12-month rating: Buy (Unchanged), FY12E US$3.50, FY13E US$3.79, PT US$40.00,Market cap. US$34.5bnSeattle Genetics, SGEN.O Matthew Roden, PhD p.4Better Than Expected Adcetris Label12-month rating: Neutral * (Unchanged) CBE , FY11E US$(1.69), FY12E US$(0.78),PT US$16.00, Market cap. US$1.31bnIndustry UpdateSemiconductors Stephen Chin p.9Semiconductor Equipment Industry Update - Weak Taiwanese semicap orderscontinueSector Comment William A. Featherston p.12North American E&P Weekly - Weekly SummaryOil Companies, Major William A. Featherston p.4Energy Sector - What if Grey or Black Skies Lie Ahead?Heavy Construction Steven Fisher, CFA p.8E&C Weekly Blueprint - Engineering & Construction UpdatePaper Products Gail S. Glazerman, CFA p.3U.S. Paper & Forest Products - August US paper/board price updateEntertainment John Janedis, CFA p.3Janedis’ Media Matters - Pressure Continues-More Than Just Macro?Internet Services Brian Pitz p.8US Internet and Interactive Entertainment - Pitz & Fitz’s Internet / IE WeeklyGlobal Strategy/EconomicsQuantitative Austin H. Burkett, CFA p.9Equity Analytics - Price Reactions to U.S. Share Repurchase AnnouncementsEquity Strategy Nicholas Smithie p.12Global Emerging Markets Fund Flows - Still no respiteThis package has been prepared by UBS Securities LLC UBS 1ANALYST CERTIFICATION AND REQUIRED DISCLOSURES BEGIN ON PAGE 13*Under review (UR) and/or exception to core rating bands (CBE) - see page : 13UBS does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may havea conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making theirinvestment decision.
  2. 2. US Morning Meeting Highlights 22 August 2011EconomicsEconomics Maury N. Harris p.10US Daily Economic Comment - Bernanke to speak in coming weekEconomics Maury N. Harris p.11US Economic Perspectives - August AngstAerospace David E. Strauss p.7U.S. Aerospace & Defense Playbook - The Week Ahead UBS 2
  3. 3. US Morning Meeting Highlights 22 August 2011Basic Materials Gail S. Glazerman, CFA............+1-212-713 3486U.S. Paper & Forest Products. AnalystAugust US paper/board price update gail.glazerman@ubs.com Overall stable, continued modest updrift in graphic paper pricesPulp & Paper Week reported August paper and board prices this weekend. August largelycontinued trends from the prior several months. They showed modest improvement in printing.and writing paper pricing and stable pricing on packaging grades. However, there were somemixed messages in uncoated free sheet. Containerboard commentary remains positiveThe newsletter suggested, consistent with our view, that broad-based pricing is unlikely giventhe current macro environment. However, they painted a fairly positive picture of current marketbalance. They report that some major producers are 2-3 weeks behind on shipments, a fewproducers are seeking modest $10-30/t price hikes in the West (apparently to account for.freight) and that export sales are fairly competitive with domestic mill nets. P&PW notes demandhas held in Aug. Graphic papers – some ups and downs (but generally up)P&PW showed modest 0.5-1% price recovery for printing & writing grades. While P&PW raiseduncoated free cut size prices $7/t, they lowered offset grades by $10/t. They raised coated.$5-10/t and uncoated groundwood by $5/t. Newsprint prices held at current levels for the 12thstraight month. Favor packaging grades – but macro is the key driver for nowWe continue to favor the outlook for paper-based packaging grades over graphic papers. Whiledemand remains a major risk given the macro back drop we see much better supply/demandtrends in packaging. Within graphic we favor uncoated free. We generally expect stable pricingover the next few months.-Consumer, Cyclical John Janedis, CFA................... +1-212-713 1064Janedis’ Media Matters. AnalystPressure Continues-More Than Just Macro? john.janedis@ubs.com What’s New? Jaime Morris, CFA, CPA............ +1-212-713 9319Media stocks remained under pressure last week, as concerns related to ad growth and Analystmargins in a downturn stay in focus. From a fundamental perspective, we believe nat’l adv. has jaime.morris@ubs.combegun to slow somewhat recently, though not materially. However, we remain on the sidelinesfor the group post our late June downgrade as we see downside to estimates for the balance of. Emily D. Woodward.................... +1-212-713 3182the year and into 2012. While valuations seem more compelling given the 17% drop in stock Associate Analystprices over that time, the group is likely more expensive than it seems. Top picks: VIA/CBS. emily.woodward@ubs.com Media M&A Conference Call TakeawaysWe hosted a conference call focused on M&A trends within the broadcast and newspapers.sectors. From a multiple perspective, TV transactions are getting done in the 7x-8x range, radiocloser to 7x and newspapers in the 4x-5x range. New York Times Linage +1% in August; WSJ Trending Down 1%Through the third wk of August, Linage at the NYT is +1% with nat’l auto -78%, dept. stores+29%, telco -9%, banks/financials -4%, and movies -21%. Classifieds are +11%, with h/w -27%,.r/e -8%, and auto +55%. Linage at the WSJ is trending down 1% in Aug (+23% comp), vs. July+3% (+21%), June +2% (+17% comp), May +8% (+7% comp), and April flat (+22% comp). ValuationLarge-cap media is trading at 6.3x our FTM EBITDA vs. 7.2x last week; mid-cap is trading at7.8x vs. 8.7x; advertising is trading at 5.2x vs. 5.6x; online recruitment is trading at 5.1x vs. 6.4x;and publishing is trading at 3.5x vs. 3.7x.- UBS 3
  4. 4. US Morning Meeting Highlights 22 August 2011Energy William A. Featherston.............+1-212-713 9701Energy Sector. AnalystWhat if Grey or Black Skies Lie Ahead? william.featherston@ubs.com Impact of recessionary commodity prices to our estimates Betty Jiang................................ +1-212-713 1287This note provides an estimate/downside risk analysis under 3 scenarios: Base case (current AnalystUBS estimates); Grey Sky & Black Sky (see Exhibit 1 for GDP and commodity price betty.jiang@ubs.comassumptions). We estimate our ‘12 E&P CFPS estimate would fall 19% & 42% & Majors EPS.estimates would fall 28% and 60% from our base case estimates under Grey and Black sky Daniel Drum.............................. +1-212-713 1151scenarios, respectively. Associate Analyst Most and least preferred names under recessionary scenarios daniel.drum@ubs.comWe prefer XOM & CVX under the Grey and Black Sky scenarios given strong balance sheet,FCF, & cheap valuation. Under both Grey & Black Skies, we see value in SWN & RRC and note Margaret OConnor...................+1-212-713 2257these gassy resource plays see further support as potential takeout candidates. We also Associate Analysthighlight APC, APA, MRO, and OXY among E&Ps, offering inexpensive valuation and margaret.o-connor@ubs.com.reasonable FCF under a Grey Sky scenario. Meanwhile, we are cautious on CHK, KWK, PXD,SD & EOG in lower oil & gas price environments given their material FCF deficit. What is different from the run up to 2008-9 recession?1) oil prices are near mid-cycle levels & gas is already near the trough while both were at spikylevels in mid-2008; 2) E&Ps have a negative 5% FCF yield today unlike the +4% in 2Q08; & 3).balance sheets are of similar strength but today’s hedge positions are at lower prices than mid-2008. Valuation: still see downside risk to Grey Sky scenarioWe see 10% and 5% downside for E&Ps & Majors valuation to reflect a Grey Sky scenario and44% & 31% downside under the Black Sky scenario, respectively.-Healthcare Matthew Roden, PhD...... +1-212-713 2491Seattle Genetics (SGEN.O). AnalystBetter Than Expected Adcetris Label matthew.roden@ubs.com What’s New? Nod to transplant-ineligible patients unexpected surprise Andrew Peters...................+1-212-713 3241This afternoon, the FDA approved Adcetris ahead of the Aug. 30th PDUFA date, with a slightly Associate Analystbroader label than was expected given FDA’s Richard Pazdur’s comments at the ODAC. The andrew.peters@ubs.comlabel includes patients who are ineligible for transplant and have failed two prior chemo. Leah Batkiewicz, PhD....... +1-212-713 4105regimens. Our forecasts include modest use in the transplant ineligible setting, and today’s Associate Analystnews puts back on the table potential upside to our above-consensus estimates. leah.batkiewicz@ubs.com Transplant-ineligible patients key factor in Adcetris market opportunityWe view the ineligible population as roughly the same size as the post-transplant opportunity, Price (18 Aug 2011).....................US$14.35and suggests a larger addressable market for Adcetris. We model $212M in 2012 US Adcetris 12-month rating.......Neutral * (Unchanged)revenues, with $50M coming from transplant ineligible patients. We had revised our model to 12m price target.......................... US$16.00.include a more modest contribution from this population following the mixed ODAC panel, but Market cap................................. US$1.31bnnow believe our above-consensus estimates may be somewhat conservative. Full-Year EPS 2011E........................................... US$(1.69) Thoughts on the stock: reviewing model on broader label, pricing, costs 2012E........................................... US$(0.78)We note the broader label offers an upside surprise to expectations, but we await additionalclarity on anticipated Opex spend following agreement with the FDA on the appropriate *Exception to core rating bands - see page 13confirmatory trials, as well as Adcetris pricing and launch timing. We note significant sensitivity.in our model on pricing changes (we assume $15k per cycle), and await further detail onMonday’s conference call. Valuation: Neutral rating with $16 price targetWe derive our price target using a risk-adjusted, DCF-based analysis.- UBS 4
  5. 5. US Morning Meeting Highlights 22 August 2011 Rajeev Jashnani, CFA..... +1-212-713CareFusion (CFN.N). 9127Update from CFO Analyst rajeev.jashnani@ubs.com Catching up with managementWe had an opportunity to speak with CFO Jim Hinrichs & VP IR Carol Cox. Summary updates Nishit Verma......................+1-212-713 2686on key business items, cost savings & M&A are below w/ more detailed thoughts on page 2. Associate AnalystNotably, regarding its hospital customers, CFN re-emphasized the challenging environment & nishit.verma@ubs.com.noted that customers’ #1 priority is to better organize, collect & deploy information within theirorganizations. Price (18 Aug 2011).....................US$23.86 12-month rating...............Buy (Unchanged) Perspective on Infusion & Dispensing 12m price target.......................... US$26.00On pumps, we believe CFN may shift sales force comp from rev-based to mgn-based in an Market cap................................. US$5.28bneffort to restore historical pricing; success in achieving this end will also be dependent on Full-Year EPScompetitive dynamics. On Dispensing, cash flows are predictable given that ~75% of units are 2011E............................................. US$1.65leased. In contrast, significant portion of revs are booked at the time of sale & could be volatile if 2012E............................................. US$1.87purchasing slows later in the fiscal yr. However, despite a tough environment in F11, CFN.posted its best year w/ ~10% bookings growth (units will be placed in F12). We believe growth islargely coming from facilities where CFN was previously not present. Streamlining co enables international M&A strategyCFN has repeatedly noted significant inefficiencies in its legal / IT structures. We estimate thatCFN can drive op mgns from 18.1% in F12 to 20.3% in F14 largely on mix (low mgn pumps tohigh mgn disposables) while we believe cost savings from streamlining the organization will beused to absorb acquisitions. Our perception is that co will internally refine its M&A strategy inthe near-term w/ a focus on ex-US expansion. We have no specific reasons to doubt CFN’s.ability to reposition the company for better growth. That said, international expansion does carrysome operational risk. Valuation-DCF-based price target of $26On CY2012 estimates, CFN trades at 12.2x EPS, 6.2x EV/EBITDA & 9% FCF yld.- UBS 5
  6. 6. US Morning Meeting Highlights 22 August 2011 Rajeev Jashnani, CFA..... +1-212-713Medtronic (MDT.N). 9127F1Q12 preview Analyst rajeev.jashnani@ubs.com We expect initial comments from new CEONew CEO Omar Ishrak’s tenure began ~2 mo’s ago, as such, initial comments may be limited; Nishit Verma......................+1-212-713 2686that said, we believe more extensive comments are likely at the 8/25 shareholder mtg. In our Associate Analystview, Ishrak needs to shape the co into an organization w/ better execution, which takes time. nishit.verma@ubs.comGiven MDT’s valuation, multiple expansion seems likely over the long-term. That said, the stock.may be range-bound in the near term until mgmt articulates a cogent plan to create value & Price (18 Aug 2011).....................US$31.25operational performance begins to stabilize in challenging core markets. 12-month rating...............Buy (Unchanged) 12m price target.......................... US$40.00 We est F1Q12 revs / EPS of $4.02B / $0.80, Street: $3.98B / $0.79 Market cap................................. US$34.5bnWe est 1% organic rev growth w/ $170M from FX (guidance: $170-190M). On EPS, we est 0% Full-Year EPSgrowth; Street at -1%. Key operational takeaways pertain to ICD & Spine franchises (combined: 2012E............................................. US$3.5038% of revs). We assume -7% mkt growth for US ICD in C2Q11 w/ MDT sales of $420M (-10%) 2013E............................................. US$3.79in their F1Q12. We est MDT ex-US ICD revs of $287M (2% cc); ex-US performance insightfulgiven competitive dynamics between MDT & STJ new products. For Spine, we est US / ex-US.revs of $613M (-3%) / $228M (4% cc). US Spine performance important to gauge Solera uptake& INFUSE-related fallout. Adjusting FY sales outlook to reflect market conditions & acquisitionsBefore factoring in recent deals, we lowered cc rev growth from 3.0% to 2.1% (2.5% to 1.5%organic) on US CRM & Spine (biologics & core). Adding ~$65M from M&A yields 2.6% cc rev.growth. Street at +1.6% (does not reflect M&A); mgmt guided to 1-3% CC in May. Wemaintained F12 EPS at $3.50 (+4%) on op ex; Street: $3.45; guidance: $3.43-3.50. Valuation – DCF-based price target of $40Our target implies a P/E of 10x on CY13 EPS. On CY12, MDT currently trades at 8.5x P/E, 6.3xEV/EBITDA & 13% FCF yld.- UBS 6
  7. 7. US Morning Meeting Highlights 22 August 2011Industrial David E. Strauss....................... +1-212-713 6185U.S. Aerospace & Defense Playbook. AnalystThe Week Ahead david.strauss@ubs.com What’s next for Aerospace and Defense? Darryl Genovesi..........................+1-212-713 4016Quiet week for A&D with Congress on recess and no major industry data points. Next week, we Associate Analysthave IATA global traffic data Tues, which we expect to reflect low- to mid-single digit growth darryl.genovesi@ubs.combased on reports out of the regions. We also have BBD earnings Wed and bizjets/helicoptersused inventory data on Thurs. Looking out, ESL reports its Q3 on Sept. 1, while GD will host an Ryan Thackston......................... +1-212-713 3321investor day in NYC on Sept. 8. DoD appears likely to begin FY12 on a CR with Congress out. Associate Analyston recess through August and likely to wait for deficit reduction Super Committee and DoD roles ryan.thackston@ubs.comand missions review before re-marking FY12 budget under new discretionary caps. Aero stocks pricing in flat to down EPS next yearCorrection has taken aero down 20%, more than the market, with group now at roughly 12x2012 consensus estimates that call for 18% growth on average (down from 31% in 2011). Aerotypically trades at mid-teens forward multiple, which we believe is appropriate assuming cycleholds up, implying that stocks now reflect expectations for flat to down EPS in 2012. Anything.but a double dip recession and we think EPS growth is much better than this and the grouprecovers. Defense budget cuts worse than indicatedOur analysis of the Deficit Reduction bill indicates the cuts to defense are larger and more frontend loaded than widely understood. We believe the DoD budget will be reduced by roughly$500B in a best case scenario with the base budget flat to down in FY12-13 and modernizationlikely 5-10% lower. If the Super Committee cant agree to additional cuts, we estimate defensewill be reduced by $1T with the FY13 budget likely 10% lower and modernization down evenmore.- Rick Paterson.................. +1-212-713 7944DHT Holdings, Inc. (DHT.N). AnalystCutting Estimates rick.paterson@ubs.com Estimates loweredDue to persistent softness in the oil tanker shipping market we are making further cuts to our Price (18 Aug 2011).......................US$2.84. 12-month rating.......Neutral * (Unchanged)DHT estimates. 2011E EPS falls from $0.37 to $0.26, and our 2012 estimate declines from 12m price target..... Prior: US$4.30 =>$0.45 to $0.33. Our quarterly dividend estimate remains $0.10. US$2.75 Perfect storm getting worse Market cap................................. US$0.18bnShipping is typically a demand and supply fundamental story, and both are hurting the stock Full-Year EPSprices at present. The industry orderbook remains extremely elevated, at 22% of the fleet on 2011E......................... US$0.37 => US$0.26order for delivery. Low new orders, vessel delivery slippage, and accelerated scrapping won’t fix 2012E......................... US$0.45 => US$0.33.that overhang anytime soon. However, the new problem is obviously the potential for global *Exception to core rating bands - seemacro weakness, hitting the demand side of the shipping equation. Not good. page 13 Our view on the stock: sit tight and clip the dividendWith a long road to recovery and heightened volatility and uncertainly, we do not recommend an.investment in DHT. For those that already own it our advice is to sit tight, be patient, and clip thedividend. ValuationWe use Net Asset Value to set a price target, and with vessel second hand values down againthis obviously pushes this lower, to $2.75 (prior $4.30) based on 1x NAV.- UBS 7
  8. 8. US Morning Meeting Highlights 22 August 2011 Steven Fisher, CFA...................+1-212-713 8634E&C Weekly Blueprint. AnalystEngineering & Construction Update steven.fisher@ubs.com Upcoming events: Petrofac, WorleyParsons, BHP results; NRC meeting Brandon Verblow........................ +1-212-713 9463Petrofac Q2 results (Aug. 22) and WorleyParsons results (Aug. 24) could have read-through to Associate Analystother E&Cs. BHP’s earnings call (Aug. 24) could offer an updated outlook on mining capex. An. brandon.verblow@ubs.comNRC meeting on the Vogtle plant COL (Aug. 25) could reveal info about possible timing for COLapproval. Highlight from this week: Blue/Grey/Black sky scenario analysisOn Aug. 16 UBS strategists published a report titled “What if Grey or Black Skies Lie Ahead?”which includes our preferred stock selections under three possible scenarios: blue skies (higherbeta-to-oil – FWLT, MDR, KBR); grey skies (diversified business, solid backlog, less non war-.related gov’t work – FLR, KBR); black skies (public sector and smaller project exposure – ACM,URS, BWC). Industry data: stock performance, Architecture Billings Index declinesThe E&C group avg stock performance over the past week was -4.7%, below the S&P 500 of -2.7%, and the E&C group avg P/E multiple on 2012 consensus is now 9.6x, below 10.2x lastweek and the current S&P 500 of 10.9x. The July Architecture Billings Index (ABI) declined to.45.1, below June’s 46.3 and is below 50 for the 4th straight month (a score below 50 indicates adecline in demand for design services). The new projects inquiry index declined as well. Sector view: Constructive on construction, despite near term turbulenceWe expect some macro-driven weakness this summer, but we still think the cyclical drivers (oilprices and backlogs) are supportive, and we like the LNG/ upstream themes. Buy ratings: KBR,MDR, FLR, FWLT, SHAW, ACM, TPC.-Technology Brian Pitz...................................+1-212-713 9310US Internet and Interactive Entertainment. AnalystPitz & Fitz’s Internet / IE Weekly brian.pitz@ubs.com Amazon Instant Video offers over 100K movies and TV Shows Brian Fitzgerald........................ +1-212-713 2851Amazon announced that Amazon Instant Video now offers customers over 100K movies and TV Analystshows. Amazon Instant Video now offers unlimited streaming of over 9,000 movies and TV brian.fitzgerald@ubs.comshows to Amazon Prime members at no extra charge to the standard $79 annual Primemembership fee. Amazon’s separate video-on-demand streaming service charges $1.99 to buy. Timothy OShea..........................+1-212-713 2140a new release TV show and $3.99 to rent a new-release movie for 24 hours. Amazon has over Associate Analyst15K HD titles in its VOD collection. timothy.oshea@ubs.com Netflix to launch in Spain, Britain in early 2012According to Reuters, Netflix will launch in Spain in the first half of 2012. Citing a conversationbetween Pedro Perez, president of the local producers association FAPAE, Spain and ScreenDaily, Reuters said that the video streaming company has been in contact with various Spanish.producers. The company is also looking to expand its services to Britain and other markets likeJapan and South Korea. Netflix launched service in Canada last fall. Foursquare users can now check in to official eventsAlthough Foursquare users have been unofficially checking into events for a long time, thecompany announced it will now officially support event check-ins for partner events. Thecompany has teamed with ESPN for sports events, MovieTicket.com for movie tickets, andSongkick for concerts to populate its database with official events. The partner events will offerusers additional check-in functionality, such as the ability to check into a specific movie theater.- UBS 8
  9. 9. US Morning Meeting Highlights 22 August 2011 Stephen Chin............................ +1-212-713 4111Semiconductor Equipment Industry Update. AnalystWeak Taiwanese semicap orders continue stephen.chin@ubs.com 3Q11 semicap orders from Taiwan are tracking down -78% q/q Mahavir Sanghavi.....................+1-212-713 4086Our own analysis of 9 Taiwanese semiconductor companies shows only $129M of total semicap Associate Analystorders were placed in the first 7 weeks of 3Q11 versus $1.1B and $2.0B in all of 2Q11 and mahavir.sanghavi@ubs.com1Q11. Total foundry semicap orders from Taiwan are tracking down -82% q/q and total DRAM.semicap orders are tracking down -52% q/q. We estimate global semicap orders likely bottom in4Q11-1Q12. Checks found TSMC placed $18M order with Applied Materials last weekOur analysis shows TSMC’s total semicap orders so far in 3Q11 are only $84M versus $820Min 2Q11 and $1.6B in 1Q11 but are likely bottoming as they are lower than its recession levelordering patterns of $300M/qtr in the 2Q08-4Q08 period. We note that Applied has received20% of TSMC total semicap orders so far in 2011 which is inline with its historical average of.22%. We expect Applied to report in line Jul-11 quarter results this week but likely guide its Oct-11 sales down -10% q/q as our checks find its Silicon orders are tracking down -20% q/q. North American Jul-11 semicap book to bill declined -9% m/m to 0.86Our review of SEMI’s monthly data showed Jul-11 semicap bookings declined -16% month overmonth to $1.3B (3rd consecutive monthly decline) as Jul-11 billings declined -8% m/m to $1.5B.We note that we are approaching similar trough bookings and book to bill levels seen in the2007 downcycle but still 10% above the 2002 and 2004 downcycles.-Quantitative Austin H. Burkett, CFA............. +1-212-713 3235Equity Analytics. AnalystPrice Reactions to U.S. Share Repurchase Announcements austin.burkett@ubs.com We examine price movements surrounding repurchase announcements.Given recent interest in share repurchases, we observed the price movements in relation toshare repurchase announcements year-to-date for the S&P 500 and Russell 2000 companies. Average 183 basis point 1-day outperformance following announcementsRussell 2000 stocks generally benefitted more with repurchase announcements, with anaverage 245 basis points of outperformance following announcements versus 103 for S&P 500.stocks. We also observed that larger repurchase announcements (as % of shares outstanding)would (intuitively) provoke larger price reactions. Relationship between dividends payers and price reactionShare repurchases are often compared to dividends, as both involve a cash transfer to.shareholders. We observed larger outperformance for companies not paying dividends relativeto those that were. Effect of prior performance on post-announcement price movementIf a stock had been performing poorly, the market may view a repurchase announcement as astatement of confidence from management in the face of underperformance. We observed thelargest 3-month underperformers benefitted the most from share repurchase announcements.- UBS 9
  10. 10. US Morning Meeting Highlights 22 August 2011Economics Maury N. Harris.........................+1-212-713 2472US Daily Economic Comment. EconomistBernanke to speak in coming week maury.harris@ubs.com Monday preview: No data. Drew T. Matus........................... +1-203-719 8378No economic data on Monday. (Note: There is no official release date for the Q2 National EconomistMortgage Delinquency Survey, although it is likely to be released in the coming week.) drew.matus@ubs.com Policy preview: Chairman Bernanke at Jackson Hole SymposiumFed Chairman Bernanke will speak on Friday at the Fed’s Jackson Hole conference, on the Samuel D. Coffin.......................+1-203-719 1252“Near- and Long-Term Prospects for the U.S. Economy”. We anticipate that Chairman Bernanke Economistwill seek to be more reassuring regarding the economic outlook than the August 9 Fed samuel.coffin@ubs.comstatement in his speech. Recent comments by FOMC Vice Chair Dudley suggest as much (seebelow). At the same time, we believe he will continue to stress that the Fed does have the tools Kevin Cummins........................ +1-203-719 1676to stimulate growth, and we expect him to spell out what those tools are without promising their Economist.use. The end goal for Chairman Bernanke, as we see it, will be to calm financial markets while kevin.cummins@ubs.combuying time for the FOMC to observe more data before taking any additional action. Data preview: Light week for economic dataAway from Jackson Hole, it is a light week for data. We expect claims to continue to inch lower,and look for another rise in the FHFA home prices index. Consumer sentiment likely recovereda bit in late August after plunging earlier. Q2 growth will probably be revised down—to 1.0%from the 1.3% originally reported. The Richmond and Kansas City Fed surveys warrant some.attention, given the collapse in the Phil. Fed survey. Durables goods orders appear to havejumped in July. NY Fed Pres Dudley still sees stronger growth in H2On Friday, NY Fed President Dudley spoke about the economy. Mr Dudley said that he expectsstronger growth in the second half of 2011, and that the recent performance of economic data is“at worst, mixed”. He noted that the recent slew of negative news was being offset by looseningcredit, stronger balance sheets, and better retail sales. He also pointed out that “[f]ollowing therelease of the FOMC’s statement, market interest rates generally removed lower, which shouldhelp provide some additional support for economic activity and jobs”. His comments on creditare consistent with the recently released Fed Sr. Loan Officer Opinion Survey for July; thatreport indicated that US bank credit conditions were- UBS 10
  11. 11. US Morning Meeting Highlights 22 August 2011 Maury N. Harris.........................+1-212-713 2472US Economic Perspectives. EconomistAugust Angst maury.harris@ubs.com The Equity Matrix Drew T. Matus........................... +1-203-719 8378Equity markets have created their own reality, and that reality may spill over into the “real Economisteconomy.” Wall Street economists been surprised by the weaker data and understandably are drew.matus@ubs.comat least somewhat less certain about their forecasts. On our part, we still do not see sufficiently.compelling evidence to merit a recession forecast. That said, we do see increased downside Samuel D. Coffin.......................+1-203-719 1252risk to the outlook from recent events. Economist Lending standards support second half samuel.coffin@ubs.comThe arguments for a double dip rely partly on tightening credit conditions—with Europeanstrains passing through into the US. However, the Fed’s Senior Loan Officer Survey indicates Kevin Cummins........................ +1-203-719 1676.that US bank credit conditions were improving through July. Banks eased lending standards Economistacross all major categories of loans, and they also reported broad increases in loan demand. kevin.cummins@ubs.com Is “worst over” for inflation?On August 9 the FOMC statement stated that officials anticipate that “inflation will settle, overcoming quarters, at levels at or below those consistent with the Committee’s dual mandate asthe effects of past energy and other commodity price increases dissipate”. However, thepersistence of broad-based gains across most categories of the core CPI, especially shelter,.raise doubts that the core can be counted on to slow. We still expect a gradual rise in underlyinginflation into 2012. The past week.The July data released over the past week suggested a strong start to the third quarter, but theAugust survey data raised concerns about recession. The week aheadAway from Jackson Hole, it is a light week for data. We expect claims to continue to inch lower,and look for another rise in the FHFA home prices index. Consumer sentiment likely recovereda bit in late August after plunging earlier. Q2 growth will probably be revised down—to 1.0%from the 1.3% originally reported. The Richmond and Kansas City Fed surveys warrant someattention, given the collapse in the Phil. Fed survey. Durables goods orders appear to havejumped in July.- UBS 11
  12. 12. US Morning Meeting Highlights 22 August 2011Equity Strategy Nicholas Smithie.......................+1-212-713 8679Global Emerging Markets Fund Flows. StrategistStill no respite nicholas.smithie@ubs.com Outflows everywhere Stephen Mo.............................+44-20-7568 4840Total GEM funds experienced strong outflows of around $2.8 billion over the last week. All the Strategistregions saw strong net selling as investors remain concerned over the European debt crisis and stephen.mo@ubs.comglobal slowdown. On a 4-week moving average basis, we have seen outflows of $1.1 billion.from Asia ex Japan; outflows of $1 billion from Dedicated GEM with EMEA and LatAm seeing Jennifer Delaney, CFA............. +1-212-713 3982outflows of $447 million and $310 million, respectively. Strategist Outflows in non-ETF funds gathers momentum jennifer.delaney@ubs.comNon-ETF funds (long-only money) have seen another week of strong outflows. With theexception of April, this group have consistently experienced net selling pressures this year. On a.4-WMA basis, ETF saw outflows of $952 million compared to outflows of $1,909 million in thenon-ETF segment. ETF flows typically make up 41% of total flow. Money flows into the defensive/domestic-demand driven marketsWe also look at the biggest movers within the geographical focused funds. The top fivedestinations for flows over the past week (as a percent of AUM) were Colombia, Mexico,.Thailand, Indonesia and the Czech Republic. The biggest net losers of funds were Taiwan,South Africa, South Korea, Russia and Malaysia. Net selling year to date compared to strong inflows last yearTotal GEM fund flows year-to-date amount to a withdrawal of $16.9 billion of funds. Thiscompares to total inflows of $84.1 billion into GEM in 2010. On a cumulative basis over $155bnhas flowed into GEM funds since January 2006.- William A. Featherston.............+1-212-713 9701North American E&P Weekly. AnalystWeekly Summary william.featherston@ubs.com Crude and natural gas finish lower after another volatile week George Toriola.......................... +1-403-695 3634Oil prices held steady through mid-week before plummeting on Thursday due to renewed AnalystEurozone debt and U.S recession fears fuelled by a trio of bearish economic news. Oil prices george.toriola@ubs.comended the week down 3.6% at $82.26/Bbl. Natural gas prices slumped throughout the week,.pushed lower by a bearish EIA storage report, falling back below $4.00/MMBtu. Prices closed Betty Jiang................................ +1-212-713 1287out the week down 3.0% to $3.94/MMBtu. Analyst E&Ps underperform the broader markets betty.jiang@ubs.com.U.S. E&Ps fell 7.6% WoW, underperforming the S&P 500, which fell 4.7%. Canadian E&Pswere also down 7.6% WoW, underperforming the TSX’s 3.8% drop. Daniel Drum.............................. +1-212-713 1151 Associate Analyst Company news daniel.drum@ubs.comNBL purchased 331,670 net acres in the SW PA & NW WV Marcellus from CNX for $3.4 billion($1.07 bn in cash over 3 years and $2.13 bn in an 8 year drilling carry) for ~$7,100/acre on an Margaret OConnor...................+1-212-713 2257NPV basis above recent deal average of ~$5,486 on an NPV basis. We upgraded OAS to “Buy” Associate Analyston above consensus ’12 volumes as we believe investors will shift focus to the ‘12 growth margaret.o-connor@ubs.comoutlook driven by an increase in drilling activity & well performance. RRC raised its resource.estimate by 1 Tcfe to 40-56 Tcfe with the increase coming from the Midcontinent and unveiled a Matthew Stephenson................+1-403-695 36376 Bcfe type curve for the NE Marcellus. Associate Analyst A look at the week ahead matthew.stephenson@ubs.comWe expect the EIA to report a 75-85 Bcf injection on Thursday.- UBS 12
  13. 13. US Morning Meeting Highlights 22 August 2011Required DisclosuresThis package has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates arereferred to herein as UBS.This package contains summaries of UBS research content. For a complete copy of the non-summarized version, please contact your UBSsales representative.For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performanceinformation; and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures. Thefigures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additionalinformation will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancybusinesses by the China Securities Regulatory Commission.UBS Investment Research: Global Equity Rating AllocationsUBS 12-Month Rating Rating Category Coverage[1] IB Services[2]Buy Buy 54% 39%Neutral Hold/Neutral 39% 35%Sell Sell 7% 14%UBS Short-Term Rating Rating Category Coverage[3] IB Services[4]Buy Buy less than 1% 33%Sell Sell less than 1% 25%1:Percentage of companies under coverage globally within the 12-month rating category.2:Percentage of companies within the 12-month rating category for which investment banking (IB) services were provided within the past 12 months.3:Percentage of companies under coverage globally within the Short-Term rating category.4:Percentage of companies within the Short-Term rating category for which investment banking (IB) services were provided within the past 12months.Source: UBS. Rating allocations are as of 30 June 2011.UBS Investment Research: Global Equity Rating DefinitionsUBS 12-Month Rating DefinitionBuy FSR is > 6% above the MRA.Neutral FSR is between -6% and 6% of the MRA.Sell FSR is > 6% below the MRA.UBS Short-Term Rating Definition Buy: Stock price expected to rise within three months fromBuy the time the rating was assigned because of a specific catalyst or event. Sell: Stock price expected to fall within three months fromSell the time the rating was assigned because of a specific catalyst or event.KEY DEFINITIONSForecast Stock Return (FSR) is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months.Market Return Assumption (MRA) is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, theequity risk premium).Under Review (UR) Stocks may be flagged as UR by the analyst, indicating that the stocks price target and/or rating are subject topossible change in the near term, usually in response to an event that may affect the investment case or valuation.Short-Term Ratings reflect the expected near-term (up to three months) performance of the stock and do not reflect any change in thefundamental view or investment case.Equity Price Targets have an investment horizon of 12 months.EXCEPTIONS AND SPECIAL CASES UBS 13
  14. 14. US Morning Meeting Highlights 22 August 2011UK and European Investment Fund ratings and definitions are: Buy: Positive on factors such as structure, management, performancerecord, discount; Neutral: Neutral on factors such as structure, management, performance record, discount; Sell: Negative on factors suchas structure, management, performance record, discount.Core Banding Exceptions (CBE): Exceptions to the standard +/-6% bands may be granted by the Investment Review Committee (IRC).Factors considered by the IRC include the stocks volatility and the credit spread of the respective companys debt. As a result, stocksdeemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, theywill be identified in the Company Disclosures table in the relevant research piece.Company DisclosuresCompany Name Reuters 12-month rating Short-term Price Price date ratingAdvantest 16 6857.T Buy N/A ¥1,018 19 Aug 2011AECOM Technology Corp. 1, 5, 16 ACM.N Buy N/A US$18.82 18 Aug 2011Alliant Techsystems 16 ATK.N Buy N/A US$57.65 19 Aug 2011Anadarko Petroleum Corp. 4a, 5, 6a, 6c, APC.N Buy N/A US$66.09 19 Aug 20117, 13, 16Apache Corporation 2, 4a, 5, 6a, 6c, 7, 16 APA.N Buy N/A US$97.03 19 Aug 2011Applied Materials Inc. 5, 16 AMAT.O Neutral N/A US$10.82 19 Aug 2011ASML 16, 24 ASML.AS Buy N/A €23.18 19 Aug 2011Babcock & Wilcox Co 16 BWC.N Neutral N/A US$21.00 18 Aug 2011BE Aerospace Inc. 2, 4a, 6a, 16, 20 BEAV.O Neutral (CBE) N/A US$30.58 19 Aug 2011Boeing Co. 4a, 5, 6a, 6b, 6c, 7, 8, 16, 18a BA.N Neutral N/A US$57.54 19 Aug 2011Canadian Natural 16 CNQ.TO Buy N/A C$33.91 18 Aug 2011CareFusion Corporation 4a, 6a, 16 CFN.N Buy N/A US$24.21 18 Aug 2011CBS Corp. 4a, 6a, 13, 16, 22 CBS.N Buy N/A US$22.04 19 Aug 2011Chesapeake Energy Corp. 4a, 6a, 16 CHK.N Neutral N/A US$29.31 19 Aug 2011Chevron Corp. 6b, 7, 16 CVX.N Buy N/A US$93.29 19 Aug 2011DHT Holdings, Inc. 2, 4a, 6a, 16, 19 DHT.N Suspended N/A US$2.89 18 Aug 2011Discovery Communications Inc 16 DISCA.O Neutral N/A US$36.32 19 Aug 2011El Paso Corp. 4a, 5, 6a, 6b, 7, 13, 16 EP.N Buy N/A US$17.75 18 Aug 2011EOG Resources 2, 4a, 6a, 16, 22 EOG.N Neutral N/A US$87.57 19 Aug 2011Esterline Technologies Corp. 16 ESL.N Neutral N/A US$62.23 19 Aug 2011ExxonMobil Corp. 3, 4a, 5, 6b, 7, 16, 18b XOM.N Neutral N/A US$69.80 19 Aug 2011Fluor Corporation 4a, 6a, 6b, 6c, 7, 13, 16 FLR.N Buy N/A US$55.14 18 Aug 2011Foster Wheeler Ltd. 5, 13, 16 FWLT.O Buy N/A US$22.41 18 Aug 2011General Dynamics Corp. 16 GD.N Buy N/A US$57.47 19 Aug 2011Goodrich Corp. 2, 4a, 5, 6a, 6b, 6c, 7, 16, 22 GR.N Buy N/A US$81.50 19 Aug 2011Hess Corp. 4a, 6a, 13, 16 HES.N Buy N/A US$54.29 19 Aug 2011Hexcel Corporation 16 HXL.N Neutral N/A US$19.17 19 Aug 2011Honeywell International Inc. 2, 4a, 5, 6a, HON.N Neutral N/A US$42.19 19 Aug 20116b, 6c, 7, 16, 18c, 22Interpublic Group of Companies, IPG.N Buy N/A US$7.74 19 Aug 2011 2, 4a, 5, 6a, 6c, 7, 13, 16, 22Inc.Jacobs Engineering Group, Inc. 16 JEC.N Neutral N/A US$32.54 18 Aug 2011KBR, Inc. 4a, 6a, 6c, 7, 16 KBR.N Buy N/A US$26.69 18 Aug 2011KLA-Tencor Corp. 16 KLAC.O Buy N/A US$33.67 19 Aug 2011LAM Research Corp. 16 LRCX.O Buy N/A US$35.99 19 Aug 2011Lockheed Martin Corp. 4a, 5, 6a, 6b, 6c, 7, LMT.N Neutral N/A US$69.39 19 Aug 201116, 22Marathon Oil Corporation 4a, 6c, 7, 16 MRO.N Buy N/A US$25.17 19 Aug 2011McDermott International 5, 16 MDR.N Buy N/A US$12.73 18 Aug 2011 UBS 14
  15. 15. US Morning Meeting Highlights 22 August 2011Company DisclosuresCompany Name Reuters 12-month rating Short-term Price Price date ratingMedtronic, Inc. 4a, 5, 6a, 6b, 6c, 7, 16 MDT.N Buy N/A US$31.25 18 Aug 2011MEMC Electronic Materials 16, 18d WFR.N Buy N/A US$5.82 19 Aug 2011Newfield Exploration Co. 13, 16 NFX.N Buy N/A US$46.74 19 Aug 2011Noble Energy, Inc. 2, 4a, 6a, 6c, 7, 16 NBL.N Buy N/A US$81.24 19 Aug 2011Northrop Grumman Corp. 16, 22 NOC.N Neutral N/A US$49.26 19 Aug 2011Novellus Systems Inc. 16 NVLS.O Neutral N/A US$26.24 19 Aug 2011Oasis Petroleum Inc 2, 4a, 6a, 16 OAS.N Buy N/A US$23.98 19 Aug 2011Occidental Petroleum Corp. 2, 4a, 5, 6a, OXY.N Buy N/A US$80.91 19 Aug 201116, 18ePetroBakken Energy Ltd. 4b, 16 PBN.TO Buy N/A C$10.67 18 Aug 2011Pioneer Natural Resources Co. 4a, 6a, PXD.N Neutral N/A US$71.91 19 Aug 201116Precision Castparts Corp. 16 PCP.N Neutral N/A US$142.45 19 Aug 2011QEP Resources Inc. 16 QEP.N Buy N/A US$33.82 18 Aug 2011Quicksilver Resources Inc. 4a, 6a, 16, 20 KWK.N Buy (CBE) N/A US$9.60 19 Aug 2011Range Resources Corp. 2, 4a, 6a, 16 RRC.N Neutral N/A US$57.45 19 Aug 2011Raytheon Co. 2, 4a, 6a, 6c, 7, 16, 22 RTN.N Neutral N/A US$39.87 19 Aug 2011Rockwell Collins Inc. 4a, 5, 6a, 6b, 6c, 7, 8, COL.N Buy N/A US$45.25 19 Aug 201116, 18fSandRidge Energy Inc 2, 4a, 6a, 16 SD.N Neutral N/A US$6.72 19 Aug 2011Seattle Genetics, Inc. 16, 20 SGEN.O Neutral (CBE) N/A US$13.95 18 Aug 2011Shaw Group Inc 4a, 6a, 6c, 7, 16, 20 SHAW.N Buy (CBE) N/A US$21.19 18 Aug 2011 4a, 6a,SWN.N Neutral N/A US$36.21 19 Aug 2011Southwestern Energy Company16Spirit AeroSystems Holdings 16 SPR.N Buy N/A US$14.63 19 Aug 2011Teradyne Inc. 5, 16 TER.N Neutral N/A US$10.90 19 Aug 2011Textron Inc. 6c, 7, 13, 16, 18g, 22 TXT.N Buy N/A US$15.21 19 Aug 2011Time Warner Inc. 2, 4a, 5, 6a, 6b, 6c, 7, 15, 16, TWX.N Neutral N/A US$27.90 19 Aug 201118hTokyo Electron 16 8035.T Buy N/A ¥3,400 19 Aug 2011TransDigm Group Inc. 2, 4a, 6a, 6c, 7, 16 TDG.N Buy N/A US$84.78 19 Aug 2011Triumph Group Inc 4a, 6a, 16 TGI.N Buy N/A US$45.65 19 Aug 2011Tutor Perini Corp. 5, 16 TPC.N Buy N/A US$13.09 18 Aug 2011Ultra Petroleum Corp. 16, 20 UPL.N Neutral (CBE) N/A US$34.81 18 Aug 2011United Technologies Corp. 4a, 8, 16, 18i UTX.N Buy N/A US$67.45 19 Aug 2011URS Corporation 4a, 6a, 16 URS.N Neutral N/A US$31.75 18 Aug 2011Varian Semiconductor Equipment VSEA.O Neutral N/A US$60.25 19 Aug 2011 16Assoc.Viacom Inc. 2, 4a, 6a, 6c, 7, 16 VIAb.N Buy N/A US$40.87 19 Aug 2011Willbros Group, Inc. 4a, 5, 6a, 16 WG.N Neutral N/A US$5.44 18 Aug 2011Source: UBS. All prices as of local market close.Ratings in this table are the most current published ratings prior to this report. They may be more recent than the stockpricing date1. UBS Securities LLC is acting as manager/co-manager, underwriter, placement or sales agent in regard to an offering of securities of this company/entity or one of its affiliates.2. UBS AG, its affiliates or subsidiaries has acted as manager/co-manager in the underwriting or placement of securities of this company/entity or one of its affiliates within the past 12 months.3. UBS Ltd is acting as financial advisor to Royal Dutch Shell plc and ExxonMobil Corporation on the sale of certain underground UBS 15
  16. 16. US Morning Meeting Highlights 22 August 2011 gas storage facilities in Germany to GDF Suez4a. Within the past 12 months, UBS AG, its affiliates or subsidiaries has received compensation for investment banking services from this company/entity.4b. Within the past 12 months, UBS Securities Canada Inc or an affiliate has received compensation for investment banking services from this company/entity.5. UBS AG, its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from this company/entity within the next three months.6a. This company/entity is, or within the past 12 months has been, a client of UBS Securities LLC, and investment banking services are being, or have been, provided.6b. This company/entity is, or within the past 12 months has been, a client of UBS Securities LLC, and non-investment banking securities-related services are being, or have been, provided.6c. This company/entity is, or within the past 12 months has been, a client of UBS Securities LLC, and non-securities services are being, or have been, provided.7. Within the past 12 months, UBS Securities LLC has received compensation for products and services other than investment banking services from this company/entity.8. The equity analyst covering this company, a member of his or her team, or one of their household members has a long common stock position in this company.13. UBS AG, its affiliates or subsidiaries beneficially owned 1% or more of a class of this company`s common equity securities as of last month`s end (or the prior month`s end if this report is dated less than 10 days after the most recent month`s end).15. UBS AG, its affiliates or subsidiaries has issued a warrant the value of which is based on one or more of the financial instruments of this company.16. UBS Securities LLC makes a market in the securities and/or ADRs of this company.18a. The U.S. equity strategist, a member of his team, or one of their household members has a long common stock position in Boeing Co.18b. The U.S. equity strategist, a member of his team, or one of their household members has a long common stock position in Exxon Mobil Corp.18c. The U.S. equity strategist, a member of his team, or one of their household members has a long common stock position in Honeywell International.18d. The U.S. equity strategist, a member of his team, or one of their household members has a long common stock position in MEMC Electronic Materials.18e. The U.S. equity strategist, a member of his team, or one of their household members has a long common stock position in Occidental Petroleum Corp.18f. The U.S. equity strategist, a member of his team, or one of their household members has a long common stock position in Rockwell Collins Inc.18g. The U.S. equity strategist, a member of his team, or one of their household members has a long common stock position in Textron Inc.18h. The U.S. equity strategist, a member of his team, or one of their household members has a long common stock position in Time Warner Inc.18i. The U.S. equity strategist, a member of his team, or one of their household members has a long common stock position in United Technologies Corp.19. Because UBS believes this security presents lower-than-normal risk, its rating is deemed Buy if the FSR exceeds the MRA by 5% and Sell if the FSR is more than 5% below the MRA (compared with 6% and 6%, respectively, under the normal rating system).20. Because UBS believes this security presents significantly higher-than-normal risk, its rating is deemed Buy if the FSR exceeds the MRA by 10% (compared with 6% under the normal rating system).22. UBS AG, its affiliates or subsidiaries held other significant financial interests in this company/entity as of last month`s end (or the prior month`s end if this report is dated less than 10 working days after the most recent month`s end).24. UBS AG, its affiliates or subsidiaries beneficially held more than 5% of the total issued share capital of this company; or for UK and Irish companies, a line of stock of this company; as of the date shown in this disclosure table.Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report.ANALYST CERTIFICATIONEach research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to eachsecurity or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views aboutthose securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or hercompensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analystin the research report.For a complete set of disclosure statements associated with the companies discussed in this report, including information on valuation and risk, UBS 16
  17. 17. US Morning Meeting Highlights 22 August 2011please contact UBS Securities LLC, 1285 Avenue of Americas, New York, NY 10019, USA, Attention: Publishing Administration.Additional Prices: Dice Holdings Inc, US$8.55 (19 Aug 2011); Discovery Holdings Ltd, RCnt3,684 (19 Aug 2011); Gannett Co., US$10.05(19 Aug 2011); Monster Worldwide Inc., US$7.27 (19 Aug 2011); New York Times Co., US$6.63 (19 Aug 2011); Omnicom Group Inc.,US$37.05 (19 Aug 2011); Scripps Networks Interactive Inc, US$38.84 (19 Aug 2011); Walt Disney Co., US$31.87 (19 Aug 2011); Source:UBS. All prices as of local market close.Additional Prices: BP, 390p (19 Aug 2011); Source: UBS. All prices as of local market close. UBS 17
  18. 18. US Morning Meeting Highlights 22 August 2011Global DisclaimerThis package has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS. In certain countries UBS AG is referred to asUBS SA.This report is for distribution only under such circumstances as may be permitted by applicable law. Nothing in this report constitutes a representation that any investment strategy or recommendation contained herein issuitable or appropriate to a recipient’s individual circumstances or otherwise constitutes a personal recommendation. It is published solely for information purposes, it does not constitute an advertisement and is not to beconstrued as a solicitation or an offer to buy or sell any securities or related financial instruments in any jurisdiction. No representation or warranty, either express or implied, is provided in relation to the accuracy,completeness or reliability of the information contained herein, except with respect to information concerning UBS AG, its subsidiaries and affiliates, nor is it intended to be a complete statement or summary of thesecurities, markets or developments referred to in the report. UBS does not undertake that investors will obtain profits, nor will it share with investors any investment profits nor accept any liability for any investment losses.Investments involve risks and investors should exercise prudence in making their investment decisions. The report should not be regarded by recipients as a substitute for the exercise of their own judgement. Pastperformance is not necessarily a guide to future performance. The value of any investment or income may go down as well as up and you may not get back the full amount invested. Any opinions expressed in this reportare subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS as a result of using different assumptions and criteria. Research will initiate, update andcease coverage solely at the discretion of UBS Investment Bank Research Management. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results.The analyst(s) responsible for the preparation of this report may interact with trading desk personnel, sales personnel and other constituencies for the purpose of gathering, synthesizing and interpreting market information.UBS is under no obligation to update or keep current the information contained herein. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS, into other areas, units,groups or affiliates of UBS. The compensation of the analyst who prepared this report is determined exclusively by research management and senior management (not including investment banking). Analyst compensationis not based on investment banking revenues, however, compensation may relate to the revenues of UBS Investment Bank as a whole, of which investment banking, sales and trading are a part.The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments isconsidered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates and other market conditions. Past performance is notnecessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this report. For investment advice, tradeexecution or other enquiries, clients should contact their local sales representative. Neither UBS nor any of its affiliates, nor any of UBS or any of its affiliates, directors, employees or agents accepts any liability for any lossor damage arising out of the use of all or any part of this report. For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC and/or UBSCapital Markets LP) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider iscarried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this research report. UBS and its affiliates and employees mayhave long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein.Any prices stated in this report are for information purposes only and do not represent valuations for individual securities or other instruments. There is no representation that any transaction can or could have been effectedat those prices and any prices do not necessarily reflect UBSs internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions, by UBS or any othersource, may yield substantially different results.United Kingdom and the rest of Europe: Except as otherwise specified herein, this material is communicated by UBS Limited, a subsidiary of UBS AG, to persons who are eligible counterparties or professional clients andis only available to such persons. The information contained herein does not apply to, and should not be relied upon by, retail clients. UBS Limited is authorised and regulated by the Financial Services Authority (FSA). UBSresearch complies with all the FSA requirements and laws concerning disclosures and these are indicated on the research where applicable. France: Prepared by UBS Limited and distributed by UBS Limited and UBSSecurities France SA. UBS Securities France S.A. is regulated by the Autorité des Marchés Financiers (AMF). Where an analyst of UBS Securities France S.A. has contributed to this report, the report is also deemed tohave been prepared by UBS Securities France S.A. Germany: Prepared by UBS Limited and distributed by UBS Limited and UBS Deutschland AG. UBS Deutschland AG is regulated by the Bundesanstalt furFinanzdienstleistungsaufsicht (BaFin). Spain: Prepared by UBS Limited and distributed by UBS Limited and UBS Securities España SV, SA. UBS Securities España SV, SA is regulated by the Comisión Nacional delMercado de Valores (CNMV). Turkey: Prepared by UBS Menkul Degerler AS on behalf of and distributed by UBS Limited. Russia: Prepared and distributed by UBS Securities CJSC. Switzerland: Distributed by UBS AG topersons who are institutional investors only. Italy: Prepared by UBS Limited and distributed by UBS Limited and UBS Italia Sim S.p.A.. UBS Italia Sim S.p.A. is regulated by the Bank of Italy and by the CommissioneNazionale per le Società e la Borsa (CONSOB). Where an analyst of UBS Italia Sim S.p.A. has contributed to this report, the report is also deemed to have been prepared by UBS Italia Sim S.p.A.. South Africa: UBS SouthAfrica (Pty) Limited (Registration No. 1995/011140/07) is a member of the JSE Limited, the South African Futures Exchange and the Bond Exchange of South Africa. UBS South Africa (Pty) Limited is an authorisedFinancial Services Provider. Details of its postal and physical address and a list of its directors are available on request or may be accessed at http:www.ubs.co.za. United States: Distributed to US persons by either UBSSecurities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a non-US affiliate), to major US institutional investorsonly. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a report prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS FinancialServices Inc. All transactions by a US person in the securities mentioned in this report must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. Canada: Distributedby UBS Securities Canada Inc., a subsidiary of UBS AG and a member of the principal Canadian stock exchanges & CIPF. A statement of its financial condition and a list of its directors and senior officers will be providedupon request. Hong Kong: Distributed by UBS Securities Asia Limited. Singapore: Distributed by UBS Securities Pte. Ltd [mica (p) 039/11/2009 and Co. Reg. No.: 198500648C] or UBS AG, Singapore Branch. Pleasecontact UBS Securities Pte Ltd, an exempt financial advisor under the Singapore Financial Advisers Act (Cap. 110); or UBS AG Singapore branch, an exempt financial adviser under the Singapore Financial Advisers Act(Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or report.The recipient of this report represent and warrant that they are accredited and institutional investors as defined in the Securities and Futures Act (Cap. 289). Japan: Distributed by UBS Securities Japan Ltd to institutionalinvestors only. Where this report has been prepared by UBS Securities Japan Ltd, UBS Securities Japan Ltd is the author, publisher and distributor of the report. Australia: Distributed by UBS AG (Holder of AustralianFinancial Services License No. 231087) and UBS Securities Australia Ltd (Holder of Australian Financial Services License No. 231098) only to Wholesale clients as defined by s761G of the Corporations Act 2001. NewZealand: Distributed by UBS New Zealand Ltd. An investment adviser and investment broker disclosure statement is available on request and free of charge by writing to PO Box 45, Auckland, NZ. Dubai: The researchprepared and distributed by UBS AG Dubai Branch, is intended for Professional Clients only and is not for further distribution within the United Arab Emirates. Korea: Distributed in Korea by UBS Securities Pte. Ltd., SeoulBranch. This report may have been edited or contributed to from time to time by affiliates of UBS Securities Pte. Ltd., Seoul Branch. Malaysia: This material is authorized to be distributed in Malaysia by UBS SecuritiesMalaysia Sdn. Bhd (253825-x).India : Prepared by UBS Securities India Private Ltd. 2/F,2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000 SEBIRegistration Numbers: NSE (Capital Market Segment): INB230951431 , NSE (F&O Segment) INF230951431, BSE (Capital Market Segment) INB010951437.The disclosures contained in research reports produced by UBS Limited shall be governed by and construed in accordance with English law.UBS specifically prohibits the redistribution of this material in whole or in part without the written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. Images may depictobjects or elements which are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2011. The key symbol and UBS are among the registered and unregistered trademarks of UBS. Allrights reserved.ab UBS 18